Literature DB >> 3493738

Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjögren's syndrome.

Y A Dalavanga, B Detrick, J J Hooks, A A Drosos, H M Moutsopoulos.   

Abstract

Labial minor salivary gland biopsy specimens from 14 patients with Sjögren's syndrome treated either with cyclosporin A (CyA) or placebo (5 mg/kg body weight day for six months) were studied to determine T lymphocyte subsets and HLA-DR antigen expression using the avidin-biotin-peroxidase technique. In all CyA treated patients we observed a decrease in the number of T lymphocytes and in the number of T helper cells, while the percentage of T suppressor cells and B cells was the same in both treated and untreated groups. It was also shown that the HLA-DR antigen expression on the epithelial cells was eliminated in the CyA treated patients. These findings suggest that the HLA-DR antigen expression on the epithelial cells is the result rather than the triggering factor of this T cell mediated process and is probably related to decreased lymphokine production by activated T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493738      PMCID: PMC1002071          DOI: 10.1136/ard.46.2.89

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

1.  Minor salivary gland involvement in Sjögren's syndrome.

Authors:  T M Tarpley; L G Anderson; C L White
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1974-01

2.  HLA-DR expression by labial minor salivary gland tissues in Sjögren's syndrome.

Authors:  H M Moutsopoulos; J J Hooks; C C Chan; Y A Dalavanga; F N Skopouli; B Detrick
Journal:  Ann Rheum Dis       Date:  1986-08       Impact factor: 19.103

3.  Mechanism of action of Cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas.

Authors:  Y Kaufmann; A E Chang; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

Review 4.  Mechanism of T cell activation: role and functional relationship of HLA-DR antigens and interleukins.

Authors:  R Palacios
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.

Authors:  A A Drosos; F N Skopouli; J S Costopoulos; C S Papadimitriou; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

6.  Use of monoclonal antibodies to analyze peripheral blood and salivary gland lymphocyte subsets in Sjögren's syndrome.

Authors:  R I Fox; S A Carstens; S Fong; C A Robinson; F Howell; J H Vaughan
Journal:  Arthritis Rheum       Date:  1982-04

7.  Treatment of intraocular inflammatory disease with cyclosporin A.

Authors:  R B Nussenblatt; A G Palestine; A H Rook; I Scher; W B Wacker; I Gery
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

8.  The in vitro regulation of human thyrocyte HLA-DR antigen expression.

Authors:  A P Weetman; D J Volkman; K D Burman; T L Gerrard; A S Fauci
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

9.  Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis.

Authors:  G Routhier; O Epstein; G Janossy; H C Thomas; P C Kung; G Goldstein
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

10.  Inhibition of T-cell activity by cyclosporin A.

Authors:  L Andrus; K J Lafferty
Journal:  Scand J Immunol       Date:  1981-05       Impact factor: 3.487

View more
  8 in total

Review 1.  Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome.

Authors:  P Oxholm; J U Prause; M Schiødt
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 2.  Lymphoepithelial interactions in the mucosal immune system.

Authors:  P Brandtzaeg; L M Sollid; P S Thrane; D Kvale; K Bjerke; H Scott; K Kett; T O Rognum
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

Review 3.  Vth International Symposium on Sjögren's syndrome. Clinical aspects and therapy.

Authors:  R I Fox
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

Review 4.  Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis.

Authors:  M Arnold; L Schrieber; P Brooks
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

5.  [Sjögren's syndrome. Current aspects from a rheumatological point of view].

Authors:  C Tomiak; T Dörner
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

6.  Lamivudine is not effective in primary Sjögren's syndrome.

Authors:  B Gescuk; A J Wu; J P Whitcher; T E Daniels; S Lund; K Fye; J C Davis
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

7.  Activation of peripheral blood lymphocytes in patients with primary Sjögren's syndrome.

Authors:  P Youinou; Y L Pennec; M A Blaschek; A Gentric; J Jouquan; A Lamour; P Angelidis
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

Review 8.  Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in Sjögren's syndrome.

Authors:  D A Sullivan; E H Sato
Journal:  Clin Immunol Immunopathol       Date:  1992-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.